MX2020002646A - Inhibidores de enpp1 y su uso para el tratamiento del cancer. - Google Patents

Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Info

Publication number
MX2020002646A
MX2020002646A MX2020002646A MX2020002646A MX2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A MX 2020002646 A MX2020002646 A MX 2020002646A
Authority
MX
Mexico
Prior art keywords
enpp1
cancer
methods
subject
inhibitor
Prior art date
Application number
MX2020002646A
Other languages
English (en)
Inventor
Mark Smith
Lingyin Li
Kelsey Erin Shaw
Jacqueline Ann Carozza
Volker Boehnert
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2020002646A publication Critical patent/MX2020002646A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos, composiciones y métodos para la inhibición de ENPP1. Aspectos de los métodos de la presente incluyen poner en contacto una muestra con un inhibidor de ENPP1 para inhibir la actividad de hidrólisis de cGAMP de ENPP1. En algunos casos, el inhibidor de ENPP1 es impermeable a las células. También se proporcionan composiciones y métodos para tratar el cáncer. Aspectos de los métodos incluyen administrarle a un sujeto una cantidad terapéuticamente eficaz de un inhibidor de ENPP1 para tratar el cáncer del sujeto. En determinados casos, el cáncer es un cáncer de tumor sólido. También se proporcionan métodos para administrar radioterapia a un sujeto ya sea antes o después de administrar un inhibidor de ENPP1. La radioterapia puede administrarse a una dosificación y/o frecuencia eficaz para reducir el daño de radiación al sujeto. En determinados casos, el método se realiza en combinación con un agente quimioterapéutico, o un inhibidor del punto de control o ambos.
MX2020002646A 2017-09-08 2018-09-07 Inhibidores de enpp1 y su uso para el tratamiento del cancer. MX2020002646A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08
PCT/US2018/050018 WO2019051269A1 (en) 2017-09-08 2018-09-07 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
MX2020002646A true MX2020002646A (es) 2020-09-25

Family

ID=63714052

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002646A MX2020002646A (es) 2017-09-08 2018-09-07 Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2023007193A MX2023007193A (es) 2017-09-08 2020-03-06 Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007193A MX2023007193A (es) 2017-09-08 2020-03-06 Inhibidores de enpp1 y su uso para el tratamiento del cancer.

Country Status (18)

Country Link
US (3) US11701371B2 (es)
EP (2) EP3678668B1 (es)
JP (2) JP7292740B2 (es)
KR (2) KR20240151869A (es)
CN (2) CN111372587B (es)
AU (3) AU2018330188C1 (es)
BR (1) BR112020004559A2 (es)
CA (1) CA3074268A1 (es)
DK (1) DK3678668T3 (es)
EA (1) EA202090595A1 (es)
ES (1) ES2975183T3 (es)
HU (1) HUE066413T2 (es)
IL (3) IL272948B2 (es)
MA (1) MA50082A (es)
MX (2) MX2020002646A (es)
PL (1) PL3678668T3 (es)
SG (1) SG11202001728YA (es)
WO (1) WO2019051269A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220056052A1 (en) * 2018-12-28 2022-02-24 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
CA3151277A1 (en) 2019-09-16 2021-03-25 Aten Porus Lifesciences Pvt. Ltd. 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein
WO2021061803A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
EP4100394B1 (en) * 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021203772A1 (en) * 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof
WO2021225969A1 (en) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
US11834512B2 (en) * 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
US20230159469A1 (en) 2020-05-08 2023-05-25 Txinno Bioscience Inc. Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof
TW202214640A (zh) 2020-06-16 2022-04-16 美商佛拉斯托醫療公司 Ｅｎｐｐ１之雜環抑制劑
US11873291B2 (en) * 2020-09-03 2024-01-16 Immunesensor Therapeutics, Inc. Quinoline cGAS antagonist compounds
WO2022091048A1 (en) 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
WO2022125613A1 (en) * 2020-12-09 2022-06-16 Stingray Therapeutics, Inc. Phosphonates as inhibitors of enpp1 and cdnp
AU2021412688B2 (en) 2020-12-29 2025-06-12 Txinno Bioscience Inc. Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
CA3204409C (en) 2021-01-29 2026-04-28 Txinno Bioscience Inc. Benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
WO2022212488A1 (en) * 2021-03-31 2022-10-06 Riboscience Llc Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4395786A4 (en) * 2021-09-03 2025-07-23 Angarus Therapeutics Inc ENPP1 INHIBITORS AND IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS
WO2023077083A1 (en) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Enpp1 inhibitors as inhibitors of metastasis
EP4486734A1 (en) 2022-03-02 2025-01-08 Immunesensor Therapeutics, Inc. Quinoline cgas antagonist compounds
CN118488950A (zh) * 2022-04-11 2024-08-13 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
EP4514331A1 (en) 2022-04-29 2025-03-05 Petragen, Inc. Inhibitors of enpp1 and modulation of bone growth
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2024028727A1 (en) * 2022-08-01 2024-02-08 Sravathi Ai Technology Private Limited Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2024213932A1 (en) * 2023-04-11 2024-10-17 The Hong Kong University Of Science And Technology Driving axon regeneration by novel enpp1 inhibitors
WO2024216211A2 (en) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of inhibiting tumor progression and metastasis by inhibition of enpp1
CN118108720B (zh) * 2023-12-28 2026-03-10 河南大学 一种苝酰亚胺衍生物pdic-ns及应用
WO2025207514A1 (en) * 2024-03-25 2025-10-02 Riboscience Llc Bicyclic heteroaryl sulfanediimine derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (en) 1923-01-16 Thomas Noble Boughton Die for forming bolts
CA190896A (en) 1919-02-24 1919-06-17 Josephat C. Bergeron Advertising device
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2002072578A2 (en) 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US20040101840A1 (en) * 2001-04-27 2004-05-27 Chung Leland W.K. Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR101676062B1 (ko) * 2009-04-11 2016-11-14 어레이 바이오파마 인크. Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제
ES2624845T3 (es) 2010-09-29 2017-07-17 Intervet International B.V. Compuestos de N-heteroarilo con unidad de puente cíclico para el tratamiento de enfermedades parasitarias
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CA2962329C (en) * 2014-09-22 2023-12-19 Yu-Sheng Chao Heterocyclic compounds and use thereof
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3233089A4 (en) * 2014-12-17 2018-11-14 Lipogen LLC Method of treating cancer with cgamp or cgasmp
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
CN110312424A (zh) 2017-01-09 2019-10-08 澳大利亚国立大学 用于改善杀虫剂的增效剂
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
MX2021009269A (es) 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Also Published As

Publication number Publication date
JP7607969B2 (ja) 2025-01-06
AU2024200148B2 (en) 2026-02-26
EP3678668A1 (en) 2020-07-15
EP3678668B1 (en) 2024-01-10
US20230103498A1 (en) 2023-04-06
US11701371B2 (en) 2023-07-18
DK3678668T3 (da) 2024-04-08
US20210369747A1 (en) 2021-12-02
CN111372587A (zh) 2020-07-03
IL272948A (en) 2020-04-30
KR20200066292A (ko) 2020-06-09
PL3678668T3 (pl) 2024-06-03
EP4327882A3 (en) 2024-05-15
WO2019051269A1 (en) 2019-03-14
AU2018330188B2 (en) 2023-10-19
IL302338A (en) 2023-06-01
AU2018330188C1 (en) 2024-02-29
EP4327882A2 (en) 2024-02-28
BR112020004559A2 (pt) 2020-09-24
ES2975183T3 (es) 2024-07-03
CA3074268A1 (en) 2019-03-14
AU2026200707A1 (en) 2026-02-19
AU2018330188A1 (en) 2020-04-23
IL302338B1 (en) 2024-06-01
IL311010A (en) 2024-04-01
RU2020112299A3 (es) 2022-03-14
IL272948B2 (en) 2023-09-01
JP2023101715A (ja) 2023-07-21
MA50082A (fr) 2020-07-15
US11707471B2 (en) 2023-07-25
JP7292740B2 (ja) 2023-06-19
AU2024200148A1 (en) 2024-01-25
IL302338B2 (en) 2024-10-01
SG11202001728YA (en) 2020-03-30
KR102715420B1 (ko) 2024-10-10
CN111372587B (zh) 2024-01-09
JP2020533288A (ja) 2020-11-19
RU2020112299A (ru) 2021-10-08
EA202090595A1 (ru) 2020-06-29
HUE066413T2 (hu) 2024-08-28
MX2023007193A (es) 2023-07-03
CN117883449A (zh) 2024-04-16
IL272948B1 (en) 2023-05-01
US20230277570A1 (en) 2023-09-07
KR20240151869A (ko) 2024-10-18

Similar Documents

Publication Publication Date Title
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201391286A1 (ru) Лечение солидных опухолей
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
WO2018102687A3 (en) Combination therapy for treating cancer
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EP4389225A3 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
EP4299127A3 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
WO2020132560A3 (en) Compositions and methods for cancer therapy
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112022009794A2 (pt) Método para tratar câncer no pulmão
MX2022006712A (es) Metodo para el tratamiento de cancer utilizando celula adyuvante artificial (aavc).
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression